Form 4: Sanara MedTech Director Roszell Mack III Receives Restricted Stock Grant Under 2024 Incentive Plan

Sanara MedTech Inc. Director Roszell Mack III was granted 3,433 shares of restricted common stock, vesting by May 2026, as part of the company's 2024 Long-Term Incentive Plan.

Summary

• Roszell Mack III, a Director of Sanara MedTech Inc. (SMTI), acquired 3,433 shares of common stock on May 22, 2025.
• These shares were granted as restricted stock under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan.
• The shares were acquired at a price of $0, indicating a grant rather than a purchase.
• Following this transaction, Roszell Mack III beneficially owns 16,534 shares of common stock directly.
• The restricted stock is set to vest on the earlier of the 2026 annual shareholder meeting or May 22, 2026, contingent upon Mr. Mack III continuing to provide services to the Company through the vesting date.

Sentiment

Score: 8

Explanation: The sentiment is positive as it represents a standard equity grant to a director, aligning their interests with the company's long-term performance and shareholder value. It's a routine compensation event rather than a significant market-moving transaction.

Positives

• The grant of restricted stock aligns the interests of Director Roszell Mack III with those of the shareholders, incentivizing long-term performance.
• The transaction is part of the Company's 2024 Omnibus Long-Term Incentive Plan, indicating a structured approach to executive and director compensation.

Negatives

• The issuance of new shares, even restricted, can lead to minor dilution for existing shareholders, though this is a standard practice for incentive plans.

Risks

• The vesting of the 3,433 restricted shares is conditional upon Roszell Mack III continuing to provide services to Sanara MedTech Inc. until the vesting date, which is either the 2026 annual shareholder meeting or May 22, 2026.

Future Outlook

The restricted stock granted to Director Roszell Mack III is expected to vest on the earlier of the 2026 annual shareholder meeting or May 22, 2026, contingent on his continued service to the company.

Industry Context

This transaction is a routine insider filing (Form 4) detailing an equity grant to a director, common practice across industries for aligning management and board interests with shareholder value. It does not provide broader industry trends or competitive insights.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term performance. There is a minor, standard dilution effect from the issuance of new shares.
• Employees/Management: This grant is part of a broader incentive plan, which can positively influence morale and retention among key personnel by demonstrating a commitment to performance-based compensation.

Next Steps

• The 3,433 shares of restricted stock will vest on the earlier of the 2026 annual shareholder meeting or May 22, 2026, subject to continued service.

Key Dates

Keywords

Sanara MedTech Inc., SMTI, Restricted Stock, Insider Transaction, Form 4, Director Compensation, Equity Grant, Long-Term Incentive Plan, Corporate Governance